Œ€‹†¬‰Κ

1)Study design of multi-center, open-label randomized controlled, head-to-headtrial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04

Uemura Y, Tanaka S, Miyazaki T, Tsukiyama M, Sone T, Taguchi A, Soen S, Moei S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) research group.

J Bone Miner Metab ; First Online: 17 July 2018 Online ISSN 1435-5604 . DOI 10.1007/s00774-018-0942-z

2)Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03

Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M.

J Bone Miner Metab ;35(4);385-395,2017.DOI 10.1007/s00774-016-0768-5

3)Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial

Imai T, Tanaka S, Kawakami K, Miyazaki T, Hagino H, Shiraki M, for the A-TOP(Adequate Treatment of Osteoporosis) Research Group.

Osteoporos Int;28(6);1893-1901,2017,DOI 10,1007/S 00198-017-3966-7

4)Validation Study of Claims-based Definitions of Suspected Atypical Femoral Fractures Using Clinical Information

Tanaka S, Hagino H, Ishizuka A, Miyazaki T, Yamamoto T, Hosoi T.

Jpn J Pharmacoepidemiol;21(1);13-19,2016,DOI.org/10.3820/jjpe.21.13

5)Comparison of expert and nonexpert physicians in the assessment of vertebral fractures using the semiquantitative method in Japan.

Uemura Y, Miyakawa N, Orimo H, Shiraki M, Nakamura T, Mori S.

J Bone Miner Metab;33(6): 642-650, 2015

6) Impact of Osteonecrosis of the Jaw on Osteoporosis Treatment in Japan: Results of a Questionnaire-Based Survey by the Adequate Treatment of Osteoporosis (A-TOP) Research@Group.

Taguchi A, Shiraki M, Tsukiyama M, Miyazaki T, Soen S, Ohta H, Nakamura T, Orimo H.

Calcif Tissue Int ;97(6);542-550, 2015

7) Serum 25 hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with high risk for fracture.

Ohta H, Uemura Y, Nakamura T, Fukunaga M, Ohashi Z, Hosoi T, Mori S, Sugimoto T, Itoi E, Orimo H, Shiraki M for the Adequate Treatment of Osteoporosis.(A-TOP)research group.

Clin Therap;36(2);225-235, 2014

8) Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03).

Tanaka S, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M.

J Bone Miner Metab;32(3); 298-304, 2014

9) Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)- 02.

Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M; A-TOP (Adequate Treatment of Osteoporosis)research group.

Curr Med Res Opin;27(6);1273-84,2011

9) Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial(JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP).

Shiraki M, Kuroda T, Hosoi T, Ohashi Y, Ohta H, Fukunaga M, Nakamura T, Orimo H et al.

J Bone Miner Metab;29(1):37-43,2011